Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving hundreds of leading biopharmaceutical companies globally:

Argus Health
UBS
Cantor Fitzgerald
Medtronic
Johnson and Johnson
Cipla
Moodys
Accenture
Healthtrust

Generated: May 28, 2018

DrugPatentWatch Database Preview

Details for New Drug Application (NDA): 021283

« Back to Dashboard

NDA 021283 describes DIOVAN, which is a drug marketed by Novartis and is included in three NDAs. It is available from nine suppliers. Additional details are available on the DIOVAN profile page.

The generic ingredient in DIOVAN is hydrochlorothiazide; valsartan. There are thirty-two drug master file entries for this compound. Twenty-seven suppliers are listed for this compound. Additional details are available on the hydrochlorothiazide; valsartan profile page.
Summary for 021283
Tradename:DIOVAN
Applicant:Novartis
Ingredient:valsartan
Patents:0
Therapeutic Class:Cardiovascular Agents
Formulation / Manufacturing:see details
Pharmacology for NDA: 021283
Medical Subject Heading (MeSH) Categories for 021283
Suppliers and Packaging for NDA: 021283
Tradename Generic Name Dosage NDA Application Type Supplier National Drug Code Package Code Package
DIOVAN valsartan TABLET;ORAL 021283 NDA Novartis Pharmaceuticals Corporation 0078-0358 N 0078-0358-34
DIOVAN valsartan TABLET;ORAL 021283 NDA Novartis Pharmaceuticals Corporation 0078-0359 N 0078-0359-34

Profile for product number 001

Active Rx/OTC/Discontinued:RXDosage:TABLET;ORALStrength80MG
Approval Date:Jul 18, 2001TE:ABRLD:Yes

Profile for product number 002

Active Rx/OTC/Discontinued:RXDosage:TABLET;ORALStrength160MG
Approval Date:Jul 18, 2001TE:ABRLD:Yes

Profile for product number 003

Active Rx/OTC/Discontinued:RXDosage:TABLET;ORALStrength320MG
Approval Date:Jul 18, 2001TE:ABRLD:Yes

Expired US Patents for NDA 021283

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Novartis DIOVAN valsartan TABLET;ORAL 021283-003 Jul 18, 2001 ➤ Sign Up ➤ Sign Up
Novartis DIOVAN valsartan TABLET;ORAL 021283-004 Aug 14, 2002 ➤ Sign Up ➤ Sign Up
Novartis DIOVAN valsartan TABLET;ORAL 021283-004 Aug 14, 2002 ➤ Sign Up ➤ Sign Up
Novartis DIOVAN valsartan TABLET;ORAL 021283-003 Jul 18, 2001 ➤ Sign Up ➤ Sign Up
Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Complete Access Available with Subscription

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Dow
Federal Trade Commission
Cantor Fitzgerald
McKinsey
Teva
Express Scripts
Covington
Harvard Business School
Argus Health

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.